Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Sources MOUNJARO TM (Tirzepatide) Injection, for Subcutaneous Use. Access Data FDA , Food and Drug Administration, Accessed 06 May 2024
Many patients switch to achieve greater weight loss, enjoy the convenience of weekly dosing, or reduce cost with compounded semaglutide
Mounjaro, on the other hand, contains a dual agonist called tirzepatide, which acts on both the GLP-1 and GIP receptors, offering more substantial appetite suppression effects than semaglutide
Some people notice lighter periods, longer gaps between cycles, or even missed cycles
Dolotov et al., 2006
High-fat diets can also slow the absorption of the drug, making it less effective
US$ 28.54
US$ 22.08
US$ 21.51
